382 related articles for article (PubMed ID: 36438960)
1. Response to subsequent antiseizure medications after first antiseizure medication failure in newly diagnosed epilepsy.
Hersi H; Saarinen JT; Raitanen J; Peltola J
Front Neurol; 2022; 13():1042168. PubMed ID: 36438960
[TBL] [Abstract][Full Text] [Related]
2. Prescribed antiseizure medication doses and their relation to defined daily doses for achieving seizure freedom in newly diagnosed patients with epilepsy.
Hersi H; Raitanen J; Saarinen JT; Peltola J
Epilepsia Open; 2023 Sep; 8(3):811-819. PubMed ID: 37010264
[TBL] [Abstract][Full Text] [Related]
3. Unanticipated improvement in seizure control in drug-resistant epilepsy- real world observations.
Moloney PB; Costello DJ
Seizure; 2021 Jan; 84():60-65. PubMed ID: 33285361
[TBL] [Abstract][Full Text] [Related]
4. Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute?
Janmohamed M; Lawn N; Spilsbury K; Chan J; Dunne J
Epilepsia; 2021 Jan; 62(1):228-237. PubMed ID: 33236785
[TBL] [Abstract][Full Text] [Related]
5. Earlier Age at Surgery for Brain Cavernous Angioma-Related Epilepsy May Achieve Complete Seizure Freedom without Aid of Anti-Seizure Medication.
Fujimoto A; Enoki H; Hatano K; Sato K; Okanishi T
Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326359
[TBL] [Abstract][Full Text] [Related]
6. Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study.
Hakeem H; Alsfouk BAA; Kwan P; Brodie MJ; Chen Z
Epilepsia; 2023 May; 64(5):1248-1258. PubMed ID: 36869855
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England.
Raspin C; Shankar R; Barion F; Pollit V; Murphy J; Sawyer L; Danielson V
J Med Econ; 2021; 24(1):1037-1051. PubMed ID: 34348576
[TBL] [Abstract][Full Text] [Related]
8. Response to first antiseizure medication in patients diagnosed with epilepsy.
Hersi H; Saarinen JT; Raitanen J; Peltola J
Acta Neurol Scand; 2021 Jul; 144(1):67-75. PubMed ID: 33835491
[TBL] [Abstract][Full Text] [Related]
9. Antiseizure medication treatment outcomes in new-onset pediatric epilepsy.
Itamura S; Sasaki K; Fujii Y; Okano R
Pediatr Int; 2023; 65(1):e15523. PubMed ID: 36912459
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of epilepsy with generalized tonic-clonic seizures alone: Clinical features, response to treatment, and likelihood of medication withdrawal.
Jaafar F; Wazne J; Hmaimess G; Nasreddine W; Beydoun A; Shatila A; Beydoun A
Epilepsia Open; 2024 May; ():. PubMed ID: 38819591
[TBL] [Abstract][Full Text] [Related]
11. Clinical factors associated with late seizure remission after failed epilepsy surgery.
Kaye LC; Poolos ZA; Miller JW; Poolos NP
Epilepsy Behav; 2023 Jan; 138():109055. PubMed ID: 36543042
[TBL] [Abstract][Full Text] [Related]
12. Real-world antiseizure medication treatment outcomes in drug-resistant focal epilepsy patients.
Hatoum HT; Arcona S; Mao J; Walton S
Epilepsia Open; 2023 Dec; 8(4):1556-1565. PubMed ID: 37842746
[TBL] [Abstract][Full Text] [Related]
13. Scoping review of rational polytherapy in patients with drug-resistant epilepsy.
Grinalds MS; Yoder C; Krauss Z; Chen AM; Rhoney DH
Pharmacotherapy; 2023 Jan; 43(1):53-84. PubMed ID: 36484111
[TBL] [Abstract][Full Text] [Related]
14. Video-EEG-monitoring to guide antiseizure medication withdrawal.
Dhaenens-Meyer LKL; Schriewer E; Weber YG; Wolking S
Neurol Res Pract; 2023 May; 5(1):20. PubMed ID: 37198666
[TBL] [Abstract][Full Text] [Related]
15. Definitions and Risk Factors for Drug-Resistant Epilepsy in an Adult Cohort.
Denton A; Thorpe L; Carter A; Angarita-Fonseca A; Waterhouse K; Hernandez Ronquillo L
Front Neurol; 2021; 12():777888. PubMed ID: 34966348
[No Abstract] [Full Text] [Related]
16. Synergistic effects of vagus nerve stimulation and antiseizure medication.
Winter Y; Sandner K; Glaser M; Ciolac D; Sauer V; Ziebart A; Karakoyun A; Chiosa V; Saryyeva A; Krauss J; Ringel F; Groppa S
J Neurol; 2023 Oct; 270(10):4978-4984. PubMed ID: 37368131
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes in drug resistant juvenile myoclonic epilepsy: Valproate resistance may not be the end of the road.
Baheti N; Rathore C; Bansal AR; Shah S; Veedu HK; Prakash S; Kanhere K; Jaiswal SK; Jukkarwala A; Murthy JMK; Radhakrishnan K
Seizure; 2021 Nov; 92():112-117. PubMed ID: 34496330
[TBL] [Abstract][Full Text] [Related]
18. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain.
Villanueva V; Serratosa JM; Toledo M; Ángel Calleja M; Navarro A; Sabaniego J; Pérez-Domper P; Álvarez-Barón E; Subías S; Gil A
Epilepsy Behav; 2023 Feb; 139():109054. PubMed ID: 36603345
[TBL] [Abstract][Full Text] [Related]
19. Effect of clinical features on antiseizure medication doses in patients with newly diagnosed epilepsy.
Hersi H; Peltola J; Raitanen J; Saarinen JT
Front Neurol; 2023; 14():1159339. PubMed ID: 37609660
[TBL] [Abstract][Full Text] [Related]
20. Treatment simplification to optimize cenobamate effectiveness and tolerability: A real-world retrospective study in Spain.
Rodríguez-Uranga JJ; Sánchez-Caro JM; Hariramani Ramchandani R
Epilepsia Open; 2024 May; ():. PubMed ID: 38800945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
